Literature DB >> 12710863

Drug interactions with cholinesterase inhibitors.

Jennifer L Defilippi1, M Lynn Crismon.   

Abstract

Cholinesterase inhibitors are used for the symptomatic treatment of patients with Alzheimer's disease. This population often has numerous comorbidities and receives treatment with multiple medications. The astute clinician should remain mindful of possible drug interactions, both pharmacokinetic and pharmacodynamic, that may occur with concomitant treatment. Although pharmacokinetic interactions have been reported, pharmacodynamic interactions play a far greater role in the significance of drug interactions, with anticholinergic medications being most concerning. Commonly prescribed medications, such as antihistamines and tricyclic antidepressants, often have anticholinergic properties that alone or in combination with one another can antagonise the effects of cholinesterase inhibitors. Other medication classes such as antipsychotics and cholinergic agents may also result in pharmacodynamic interactions. However, for the most part, cholinesterase inhibitors can be used safely in combination with other medications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12710863     DOI: 10.2165/00002512-200320060-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  28 in total

1.  Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium.

Authors:  L Tune; S Carr; E Hoag; T Cooper
Journal:  Am J Psychiatry       Date:  1992-10       Impact factor: 18.112

2.  Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo.

Authors:  J T Larsen; L L Hansen; O Spigset; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1999-07       Impact factor: 2.953

3.  Extrapyramidal side effects in a patient treated with risperidone plus donepezil.

Authors:  T M Magnuson; B K Keller; W J Burke
Journal:  Am J Psychiatry       Date:  1998-10       Impact factor: 18.112

4.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

Authors:  R A Mulnard; C W Cotman; C Kawas; C H van Dyck; M Sano; R Doody; E Koss; E Pfeiffer; S Jin; A Gamst; M Grundman; R Thomas; L J Thal
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

5.  Use of anticholinergic medications by older adults with dementia.

Authors:  Catherine M Roe; Michael J Anderson; Barney Spivack
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

6.  Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.

Authors:  L S Schneider; M R Farlow; V W Henderson; J M Pogoda
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

7.  The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.

Authors:  P J Tiseo; K Foley; L T Friedhoff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

8.  Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers.

Authors:  P J Tiseo; K Foley; L T Friedhoff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

9.  Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses.

Authors:  P J Tiseo; C A Perdomo; L T Friedhoff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

10.  Inhibition of tacrine oral clearance by cimetidine.

Authors:  S T Forgue; P A Reece; A J Sedman; T M deVries
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875

View more
  8 in total

1.  Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.

Authors:  Virginie Gardette; Sandrine Andrieu; Maryse Lapeyre-Mestre; Nicola Coley; Christelle Cantet; Pierre-Jean Ousset; Alain Grand; Jean-Louis Monstastruc; Bruno Vellas
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 3.  Poststroke aphasia : epidemiology, pathophysiology and treatment.

Authors:  Marcelo L Berthier
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Epidemiology of drug-disease interactions in older veteran nursing home residents.

Authors:  Sherrie L Aspinall; Xinhua Zhao; Todd P Semla; Francesca E Cunningham; Allison M Paquin; Mary Jo Pugh; Kenneth E Schmader; Roslyn A Stone; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2014-12-23       Impact factor: 5.562

5.  Ten-year trajectory of potentially inappropriate medications in very old women: importance of cognitive status.

Authors:  Alain Koyama; Michael Steinman; Kristine Ensrud; Teresa A Hillier; Kristine Yaffe
Journal:  J Am Geriatr Soc       Date:  2013-01-15       Impact factor: 5.562

6.  Anti-dementia drugs and co-medication among patients with Alzheimer's disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem).

Authors:  Seyed-Mohammad Fereshtehnejad; Kristina Johnell; Maria Eriksdotter
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

7.  Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

Authors:  Neda Tavassoli; Agnes Sommet; Maryse Lapeyre-Mestre; Haleh Bagheri; Jean-Louis Montrastruc
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

8.  Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians.

Authors:  Elke Jeschke; Thomas Ostermann; Horst C Vollmar; Manuela Tabali; Friedemann Schad; Harald Matthes
Journal:  BMC Neurol       Date:  2011-08-08       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.